Skip to content
iStock 1399287318 | Quentinvest
Subscribers Only
Investment Alerts

Novo Nordisk sets out to conquer obesity

March 9, 2023

This is a great chart for a great company with an important 'something new' to drive the shares still higher. Novo Nordisk is better known for its diabetes treatments and there are many exciting innovations coming along here.

We are excited by the potential of once-weekly insulin icodec, which has successfully completed the phase 3 ONWARDS programme, demonstrating superior reductions in blood glucose levels compared to once-daily basal insulin degludec and insulin glargine in insulin naïve people with type 2 diabetes.

The launch of a 2.0 mg dose of our once-weekly GLP-1 injection Ozempic® in the US has increased options for patients, while Rybelsus® is continuing to expand choice in the oral anti-diabetic space. Looking to the future, our new CagriSema experimental therapy for type 2 diabetes – a combination of the established GLP-1 semaglutide and the long-acting amylin analogue cagrilintide – is set to enter phase 3 development in 2023 following promising phase 2 results.

Annual report 2022

More explosive growth is coming from its obesity drug Wegovy, which is the obesity bit in the graphic below.

To continue reading this article...


Already a subscriber?

Further reading

More >
iStock 486691192 | Quentinvest
Subscribers Only
Investment Alerts

US Inc. v UK plc – a Tale of Two Charts

March 27, 2023
iStock 1473420344 | Quentinvest
Subscribers Only
Investment Alerts

Barclays Walks a Stock Chart Tightrope

March 24, 2023
iStock 606003002 | Quentinvest
Subscribers Only
Investment Alerts

Pros and Cons of Big Picture Share Trading Indicators

March 23, 2023
iStock 1307254034 | Quentinvest
Subscribers Only
Investment Alerts

Bitcoin at $1 Million – Why Not?

March 22, 2023